A degradable lipid selected through cell experiments and machine learning increased functional RNA delivery in mouse liver. Independent animal tests measured greater protein production and gene recombination for PA97MD101 than for a comparator at a matched dose. The peer-reviewed study separates those experimental gains from unestablished long-term safety and therapeutic benefit in humans.
A peer-reviewed mouse study identified PA97MD101, a degradable ionizable lipid used in tiny RNA carrying particles, as a candidate for more effective liver delivery. At a matched dose, it showed about 4 times the liver luciferase output of comparator SM102. Luciferase is a light-producing protein used to measure expression. Nanoparticle accumulation in the liver was broadly similar despite the different functional output.[1]
Researchers screened 520 lipids assembled from 13 tails and 40 head groups in HeLa, a laboratory cell line. A machine-learning model trained on these intracellular delivery measurements prioritised candidates from 10,920 virtual compounds. Selected lipids were then synthesised and independently tested in animals; organ distribution and liver-cell specificity were outside the training target.[1]
Nanoparticles carrying messenger RNA for the Cre recombination enzyme showed a lasting fluorescence change in reporter mice. Liver-level recombination rose approximately 6.75-fold, and gene-editing cargo targeting Ttr reduced its liver RNA and serum protein. Core comparisons used 3 independent mice per group. Activity was higher in a liver-cell-enriched population; long-term safety and therapeutic benefit in humans remain unestablished.[1]
